Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491171 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL29491144 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL2359208 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL16428213 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL22650747 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL29491151 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL22650600 | 0.77 | MAPK14 (0.40) | SMN1; SMN2CDK2CDK1HTR3ACCNA2 | |
| SCHEMBL29491131 | 0.77 | MAPK14 (0.40) | SMN1; SMN2CDK2CDK1HTR3ACCNA2 | |
| SCHEMBL16437310 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2CDK2CDK1CCNB1CCNE1 | |
| SCHEMBL22650364 | 0.76 | CDK4 (0.37) | SMN1; SMN2CDK2HTR3ACCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325544-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250275971-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12285429-B2 | CDK inhibitors | GENENTECH, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240033264-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| WO-2021226140-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033264-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | SMN1; SMN2 2631/4885CDK2 10/4885CDK1 5/4885 |
| US-20240066031-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | SMN1; SMN2 2631/4885CDK2 10/4885CDK1 5/4885 |
| US-12285429-B2 | CDK inhibitors | CDK9, CDK3, CDKL1 | SMN1; SMN2 2470/4885CDK2 8/4885CDK1 5/4885 |
| US-20250325544-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | SMN1; SMN2 2041/4885CDK2 11/4885CDK1 4/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | SMN1; SMN2 2350/4885CDK2 11/4885CDK1 7/4885 |
| US-20230174512-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | SMN1; SMN2 2631/4885CDK2 10/4885CDK1 5/4885 |
| US-20250275971-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | SMN1; SMN2 2041/4885CDK2 11/4885CDK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.